유세포분석 시장 예측(-2030년) : 제품별, 기술별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Flow Cytometry Market is accounted for $5.17 billion in 2023 and is expected to reach $10.14 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Flow Cytometry is a laser-based technique which is used to detect and analyze chemical or physical characteristics of cells or particles, which is most commonly used to evaluate bone marrow, peripheral blood and other fluids in your body. Flow cytometry is continuously going through new developments with availability of robust photo detectors and new laser emitters, use of LED lamps as emitter, and changes in analytical capacity (multidimensional analysis software).

According to a World Health Organization report, cancer became the major cause of death in 2020, with 10 million in approximation, where often cases were of breast cancer (2.26 million), lung (2.21 million), colon and rectum (1.93 million); prostate (1.41 million), skin (1.20 million) and stomach (1.09 million).

Market Dynamics:

Driver:

Instrumental improvements in flow cytometry technology

The development and commercialization of technologically cutting-edge flow cytometry solutions that offer streamlined workflows, simplicity of use, and quicker turnaround times is becoming the focus of major businesses operating in the global market. Especially in developed markets where the adoption rate of technologically cutting-edge items is high, such innovative products are anticipated to have significant demand rise during the projection period. For instance, CellMek SPS, a fully automated sample preparation system for clinical flow cytometry, was introduced by Beckman Coulter, a Danaher Corporation division.

Restraint:

High product costs

Several flow cytometry instruments are needed by the majority of end users, including clinical laboratories, significant research institutions, and pharmaceutical corporations, in order to conduct numerous research studies at once. The capital cost of purchasing and maintaining these gadgets consequently rises significantly as a result. Additionally, the overall increase in the total cost of ownership of these instruments is brought on by maintenance charges and a number of other indirect expenses. In light of this, high product installation costs and associated costs impede the best use of flow cytometry devices in clinical and research applications, particularly in emerging nations. Furthermore, flow cytometry equipment costs more money because it has more sophisticated features and functionalities. The cost of cell sorters using flow cytometry is higher than that of cell analyzers.

Opportunity:

Public-private funding initiatives in stem cell research

Global stem cell research activities are driven in part by favorable regulatory environments in developing nations, a large number of stem cell product pipelines, and an increase in the use of stem cells in the treatment of various diseases. Additionally, this is supported by the growing number of research initiatives and monetary contributions from public and commercial entities in the stem cell research sector. Three researchers from Stanford University (US) have received a USD 31 million grant from the California Institute for Regenerative Medicine (US) to begin the first-ever clinical studies using stem cells to treat heart failure, stroke, and a particular form of brain and spinal cord malignancy.

Threat:

Limitations in sample preparation and handling

Sample stability is a crucial consideration. Some samples, especially certain cell types or biomolecules, may be inherently unstable or prone to degradation, leading to changes in their characteristics over time. This instability can affect the accuracy and reproducibility of flow cytometry measurements, resulting in unreliable data. Proper storage conditions, appropriate fixatives, and handling techniques are necessary to maintain sample stability, but these requirements can be demanding and time-consuming. Furthermore, the variability in sample processing techniques can introduce inconsistencies in results. Different researchers or laboratories may employ diverse protocols for sample preparation, including sample staining, cell isolation, and purification.

COVID-19 Impact:

The COVID-19 pandemic had a favorable effect on the prospects for the flow cytometry business during the initial COVID-19 epidemic. The increased market share of flow cytometry reagents has increased the utilization of flow cytometry technology by boosting the use of reagents in research and clinical trials. For instance, in March 2020, Cytek Biosciences Inc. assisted scientists and doctors from all over the world in their investigation of the COVID-19 virus's effects on human immune systems. Comparing COVID-19 patients to recovered donors and healthy donors, flow cytometry revealed that COVID-19 patients had lower B-cell and T-cell frequencies.

The clinical segment is expected to be the largest during the forecast period:

The clinical segment is anticipated to have a bigger revenue share over the forecast period. The rise in cancer and infectious disease research and development, especially COVID-19, is to blame for this high percentage. Additionally, growing R&D expenditures in the pharmaceutical and biotechnology sectors are probably going to foster a favorable atmosphere for market expansion. The launch of innovative flow cytometry technologies for clinical applications and ongoing growth strategies by key players in the market are also projected to considerably support segment growth.

The bead-based flow cytometry segment is expected to have the highest CAGR during the forecast period:

The bead-based flow cytometry segment is anticipated to experience consistent revenue growth over the course of the projection period. Growth factors, cytokines, chemokines, and phosphorylated cell signalling proteins can all be measured using bead-based flow cytometry. An ideal instrument for carrying out multiplex bead-based tests is thought to be the high-throughput flow cytometry technique. Due to developments in molecular engineering and monoclonal antibody production as well as the benefits they bring, including cost effectiveness, quick turnaround times, and micro sampling capabilities, the demand for these tests is predicted to expand significantly over the anticipated period.

Region with largest share:

In the global market over the forecast period, North America is anticipated to have the greatest revenue share with high penetration of flow cytometry technologies among key end users. However, this market is still expected to offer high growth opportunities because of the expanding application areas of flow cytometry in clinical settings. Factors such as the presence of a favorable business environment, growing government support through funds and grants, the high prevalence of HIV/AIDS and cancer, the growing focus on the development of treatment options for target diseases (such as cancer and immunological disorders), and the strong presence of key players are driving the growth of the market in the region.

Region with highest CAGR:

The market in Asia Pacific is anticipated to rise steadily over the course of the forecast period. Asia Pacific has been experiencing rapid development in its healthcare infrastructure, with increased investments in healthcare facilities, research institutes, and laboratories. Additionally, Global flow cytometry manufacturers are establishing collaborations and partnerships with regional players and distributors to expand their presence in the Asia Pacific market. These partnerships help in enhancing product availability, providing local technical support, and addressing the specific needs of customers in the region, which propels market growth in the region over the forecast period.

Key players in the market

Some of the key players in Flow Cytometry market include Accellix, Agilent Technologies Inc., Apogee Flow Systems Ltd., Beckman Coulter, Inc. (Danaher), Becton, Dickinson and Company, BioMerieux SA, Bio-Rad Laboratories, Cytek® Biosciences, Enzo Biochem Inc., FURUKAWA ELECTRIC CO., LTD., Hamamatsu Photonics K.K, Life Technologies Corporation (Thermo Fisher Scientific Inc.), Luminex Corporation, Merck KGaA, Miltenyi Biotech, Sartorius AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Sony Biotechnology Inc. (Sony Corporation of America), Stratedigm Inc. and Sysmex Corporation.

Key Developments:

In November 2022, Sony Corporation released SFA-Life Sciences Cloud Platform, a cloud-based solution for analyzing flow cytometry data that makes it easy to find rare cells like cancer cells and stem cells in a large number of cell populations

In June 2022, BD (US) launched BD FACSDiscover S8 Cell Sorter with high-speed imaging technology that sorts cells based on visual characteristics

In March 2022, Beckman Coulter, Inc. (US) launched a fully automated sample preparation system (SPS) CellMek SPS, which offers on-demand processing for many sample types to help laboratories expand capabilities

In January 2022, Sony Biotechnology, Inc. presented a novel closed cell isolation system CGX10 for use in GMP-compliant cell sorting applications. With the initiative, new growth opportunities were hoped for the company. Such advances in technology will lead to cost-effectiveness, greater accuracy and portability and are likely to create future growth opportunities

Products Covered:

• Reagents and Consumables
• Instruments
• Services
• Software
• Other Products

Technologies Covered:

• Cell-based Flow Cytometry
• Bead-based Flow Cytometry

Applications Covered:

• Research Applications
• Clinical Applications
• Industrial Applications

End Users Covered:

• Academic
• Research Institutes
• Hospitals
• Pharmaceutical
• Biotechnology Companies

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Flow Cytometry Market, By Product

• 5.1 Introduction
• 5.2 Reagents and Consumables
• 5.3 Instruments
  • 5.3.1 Cell Analyzers
    • 5.3.1.1 High-range
    • 5.3.1.2 Mid-range
    • 5.3.1.2 Low-range
• 5.4 Services
• 5.5 Software
• 5.6 Other Products

6 Global Flow Cytometry Market, By Technology

• 6.1 Introduction
• 6.2 Cell-based Flow Cytometry
• 6.3 Bead-based Flow Cytometry

7 Global Flow Cytometry Market, By Application

• 7.1 Introduction
• 7.2 Research Applications
  • 7.2.1 Pharmaceuticals and Biotechnology
    • 7.2.1.1 Drug Discovery
    • 7.2.1.2 Stem Cell Research
    • 7.2.1.3 In Vitro Toxicity Testing
  • 7.2.2 Immunology
  • 7.2.3 Cell Sorting
  • 7.2.4 Apoptosis
  • 7.2.5 Cell Cycle Analysis
  • 7.2.6 Cell Viability
  • 7.2.7 Cell Counting
• 7.3 Clinical Applications
  • 7.3.1 Cancer Diagnostics
  • 7.3.2 Hematology
  • 7.3.3 Autoimmune Diseases
  • 7.3.4 Organ Transplantation
• 7.4 Industrial Applications

8 Global Flow Cytometry Market, By End User

• 8.1 Introduction
• 8.2 Academic
• 8.3 Hospitals
• 8.4 Pharmaceutical
• 8.5 Biotechnology Companies
• 8.6 Research Institutes

9 Global Flow Cytometry Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Accellix.
• 11.2 Agilent Technologies Inc.
• 11.3 Apogee Flow Systems Ltd.
• 11.4 Beckman Coulter, Inc. (Danaher)
• 11.5 Becton, Dickinson and Company
• 11.6 BioMerieux SA
• 11.7 Bio-Rad Laboratories
• 11.8 Cytek® Biosciences
• 11.9 Enzo Biochem Inc.
• 11.10 FURUKAWA ELECTRIC CO., LTD.
• 11.11 Hamamatsu Photonics K.K
• 11.12 Life Technologies Corporation (Thermo Fisher Scientific Inc.)
• 11.13 Luminex Corporation
• 11.14 Merck KGaA
• 11.15 Miltenyi Biotech
• 11.16 Sartorius AG
• 11.17 Shenzhen Mindray Bio-Medical Electronics Co., Ltd
• 11.18 Sony Biotechnology Inc. (Sony Corporation of America)
• 11.19 Stratedigm Inc.
• 11.20 Sysmex Corporation